Inflammatory markers and extended erythrocyte phenotyping in sickle cell patients: a systematic review of diagnostic and clinical implications
International Journal of Scientific Research and Innovative Studies · 01.06.2026 · 5 (3) · 515-524
DOI: 10.63883/ijsrisjournal.v5i3.784 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift International Journal of Scientific Research and Innovative Studies, online erschienen am 01.06.2026. Verfasst von Arold FAZILI OZENGA und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Sickle cell disease (SCD) requires chronic blood transfusions, which introduce a severe risk of erythrocyte alloimmunization. This systematic review and meta-analysis evaluate the dual impact of extended red blood cell phenotyping and circulating inflammatory biomarkers on alloimmunization rates. Methodology: Following PRISMA 2020 guidelines, electronic databases were searched up to April 30, 2026, for multi-continental studies published since 2015. A random-effects model synthesized data from 42 eligible studies to compute pooled prevalence and odds ratios (OR). Meta-regression explored geographic resource inequalities as potential moderators of statistical heterogeneity.
Results
The global pooled prevalence of red blood cell alloimmunization across all SCD cohorts was 22.7% (95% CI: 18.4%–27.6%). Stratified analysis revealed that limited ABO/RhD-only matching centers faced a massive 48.3% sensitization rate, whereas centers utilizing extended minor antigen phenotyping (Rh, Kell, Duffy, MNS, Kidd) dropped to 7.1%. Severe inter-study heterogeneity (I2 = 87.5%) was fully explained by geographic location (meta-regression p = 0.008), highlighting a critical burden in resource-constrained Central African regions. Furthermore, simultaneous elevation of C-reactive protein, interleukin-6, and serum ferritin significantly heightened the risk of developing alloantibodies, yielding a pooled odds ratio of 3.1 (95% CI: 2.41–3.98, p < 0.001).
Conclusion
Extended immunohematology matching drastically reduces erythrocyte sensitization. Chronic systemic inflammation acts as an independent pro-sensitizing clinical risk factor, lowering the threshold for antibody production. Integrating pre-transfusion inflammatory monitoring and molecular genotyping into routine healthcare pathways is essential to optimize transfusion safety in both high-burden and resource-limited settings. Keywords: Sickle Cell Disease; Alloimmunization; Extended Erythrocyte Phenotyping; Inflammatory Biomarkers; Systematic Review. Received Date: April 21, 2026 Accepted Date: May 12, 2026 Published Date: June 01, 2026 Available Online at: https://www.ijsrisjournal.com/index.php/ojsfiles/article/view/784
Zitieren
APA
OZENGA, A. F., VIRIMA, M., & KOTO-TE-NYIWA, J. N. (2026). Inflammatory markers and extended erythrocyte phenotyping in sickle cell patients: a systematic review of diagnostic and clinical implications. International Journal of Scientific Research and Innovative Studies, 5(3), 515-524. https://doi.org/10.63883/ijsrisjournal.v5i3.784
Vancouver
OZENGA AF, VIRIMA M, KOTO-TE-NYIWA JN. Inflammatory markers and extended erythrocyte phenotyping in sickle cell patients: a systematic review of diagnostic and clinical implications. International Journal of Scientific Research and Innovative Studies. 2026;5(3):515-524. doi:10.63883/ijsrisjournal.v5i3.784
BibTeX
@article{OZENGA2026,
author = {OZENGA, Arold FAZILI and VIRIMA, MUDOGO and KOTO-TE-NYIWA, Jean-Paul NGBOLUA},
title = {Inflammatory markers and extended erythrocyte phenotyping in sickle cell patients: a systematic review of diagnostic and clinical implications},
journal = {International Journal of Scientific Research and Innovative Studies},
year = {2026},
volume = {5},
number = {3},
pages = {515--524},
doi = {10.63883/ijsrisjournal.v5i3.784}
}
EUVIMED